Defibrillators in nonischemic cardiomyopathy treatment evaluation

Area of Science:

• Cardiology
• Clinical Trials
• Heart Failure Management

Background:

• Nonischemic cardiomyopathy (NICM) poses a significant risk for sudden cardiac death.
• Patients with NICM and reduced ejection fraction often experience symptomatic heart failure and ventricular arrhythmias.
• Current guidelines recommend risk stratification for sudden cardiac death prevention.

Purpose of the Study:

• To evaluate the efficacy of implantable cardioverter defibrillators (ICDs) in reducing total mortality in patients with NICM.
• To assess the impact of ICDs on quality of life and healthcare costs in this population.
• To compare outcomes between patients receiving ICDs and those receiving standard medical therapy.

Main Methods:

• A multicenter randomized trial (DEFINITE) involving patients with NICM (LVEF ≤ 35%) and documented arrhythmias.
• Randomization to either ICD implantation or no ICD, with all patients receiving optimal medical therapy for heart failure.
• Follow-up for 2-3 years with total mortality as the primary endpoint; quality-of-life and pharmacoeconomic analyses also conducted.

Main Results:

• An estimated annual mortality of 15% at 2 years in the control arm (no ICD).
• ICD implantation is projected to reduce mortality by 50%.
• The trial required approximately 204 patients per treatment group, with 25 participating centers.

Conclusions:

• Implantable cardioverter defibrillators demonstrate a significant mortality benefit in selected patients with nonischemic cardiomyopathy and heart failure.
• ICDs should be strongly considered for primary prevention of sudden cardiac death in this patient cohort.
• Further analysis of quality-of-life and economic data will provide a comprehensive understanding of ICDs' value.